Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Wang Chung KwokJames Chung Man HoTerence Chi Chun TamMary Sau Man IpDavid Chi Leung LamPublished in: Thoracic cancer (2022)
First-line afatinib, followed by osimertinib upon disease progression with T790M mutation, demonstrated significantly longer OS compared to that using other EGFR-TKI in the first-line setting.